Application of solanesol in preparation of medicine for repairing oral ulcer

By regulating the PI 3K-Akt, TRP, TNF and p53 signaling pathways with solanesol, the problems of large drug side effects and complicated medication in the treatment of oral ulcers have been solved, and safe and effective oral ulcer repair has been achieved.

CN119033739APending Publication Date: 2024-11-29PEKING UNIV SCHOOL OF STOMATOLOGY
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411293058.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing treatments for oral ulcers suffer from significant drug side effects or complex medication regimens, resulting in low patient compliance. The safety and efficacy of emerging treatment methods have not yet been confirmed.

Method used

Solanesol was used as a regulator of the PI 3K-Akt, TRP, TNF and p53 signaling pathways, and an appropriate concentration range of 100-1000 μmol/L was determined for topical application to promote the repair of oral ulcers.

Benefits of technology

It promotes the repair of oral ulcers, significantly reduces the ulcer area, has good efficacy, high safety, simple operation, and improves patient compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033739A_ABST
    Figure CN119033739A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of oral medicine, in particular to application of solanesol in preparation of a medicine for promoting dental ulcer repair. Based on an established mouse oral ulcer model, solanesol is used as a PI 3K-Akt signal channel regulator, a TRP signal channel regulator, a TNF signal channel regulator and a p53 signal channel regulator, and a series of cell application concentration experiments are carried out. The technical scheme that solanesol with a specific concentration is used as the medicine component for promoting dental ulcer repair is determined, the characteristics of good curative effect and high safety are achieved, the operation is convenient in practical application, and the patient compliance during dental ulcer treatment is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of oral medicine, and in particular to application of solanesol in preparing a medicine for promoting the repair of oral ulcers. Background Art

[0002] Oral ulcers are a common oral mucosal lesion that mainly occurs in the non-keratinized oral mucosal area of ​​patients. The ulcers are usually round or oval, with clear edges, surrounded by erythema, and yellow or gray at the bottom. Since oral ulcers are multiple and recurrent, and can cause severe pain in patients, affecting chewing, eating, and language communication functions, appropriate measures need to be taken for prevention and treatment.

[0003] There are many ways to deal with oral ulcers, including lifestyle adjustments, traditional methods such as Western medicine and Chinese medicine, and other emerging treatments. Among them, lifestyle adjustments refer to avoiding spicy and acidic foods, maintaining oral hygiene, and reducing stress, which usually require patients to invest time and make continuous efforts, so they are generally used to prevent oral ulcers rather than treat them.

[0004] In terms of western medicine treatment, local medication and systemic medication are involved. Among them, local medication should be the first choice for patients with smaller ulcers or fewer ulcers. This treatment method usually uses analgesic ointments, anti-inflammatory ointments and anti-infective drugs that can act directly on the ulcer site, thereby relieving pain or helping the oral mucosa heal to a certain extent. But at the same time, these drugs also have some negative problems. For example, local anesthetic ointments can quickly relieve pain, but long-term use may cause local tissue numbness and do not promote healing; steroid ointments can effectively reduce inflammation and pain, but long-term use may cause local tissue atrophy and affect the healing process. When oral ulcers are more severe, systemic medication is required, such as intravenous antibiotics. This method is ineffective for non-infectious ulcers. At the same time, although this method can effectively deal with bacterial infections, it may also lead to drug resistance.

[0005] In terms of TCM treatment, oral ulcers are generally believed to be related to internal heat, and treatment aims to harmonize yin and yang, clear away heat and detoxify through oral and external application of Chinese medicine and acupuncture. The advantages of this treatment method are multi-target effects and fewer side effects, which are suitable for long-term conditioning, but the mechanism of action of the treatment is relatively complex, the treatment cycle is long, and it takes a long time to be effective. In addition, due to the lack of unified treatment standards and efficacy evaluation systems, the effectiveness of TCM treatment is difficult to evaluate.

[0006] In addition, people have also explored some emerging treatment methods to deal with oral ulcers, such as laser therapy, photodynamic therapy and gene therapy. These methods aim to promote ulcer healing and reduce inflammation, but they are still in the research stage, and their safety and effectiveness need to be further verified.

[0007] In summary, the above-mentioned mainstream treatment methods are usually accompanied by large drug side effects or complex medication regimens, resulting in low patient compliance. The safety and effectiveness of emerging treatment methods remain to be confirmed. Therefore, it is still necessary to find suitable drugs to provide patients with oral ulcers with safe, effective and simple treatment options. Summary of the invention

[0008] The invention provides oral ulcer repair regulators for PI 3K-Akt signaling pathway, TRP signaling pathway and TNF signaling pathway. The regulators comprise solanesol (Sol anesol, Sol) with a concentration of 100-750 μmol / L.

[0009] The invention provides a p53 signaling pathway oral ulcer repair regulator, which comprises solanesol with a concentration of 750-1000 μmol / L.

[0010] The invention provides oral ulcer repair regulators for PI 3K-Akt signaling pathway, TRP signaling pathway, TNF signaling pathway and p53 signaling pathway. The regulators comprise solanesol with a concentration of 100-1000 μmol / L.

[0011] The invention provides application of solanesol in preparing oral ulcer repair regulators of PI 3K-Akt signaling pathway, TRP signaling pathway and TNF signaling pathway, wherein the concentration of the solanesol is 100-750 μmol / L.

[0012] The invention provides application of solanesol in preparing a p53 signaling pathway oral ulcer repair regulator, wherein the concentration of the solanesol is 750-1000 μmol / L.

[0013] The invention provides application of solanesol in preparing oral ulcer repair regulators for PI 3K-Akt signaling pathway, TRP signaling pathway, TNF signaling pathway and p53 signaling pathway, wherein the concentration of the solanesol is 100-1000 μmol / L.

[0014] Compared with the prior art, the beneficial effect of the present invention is that solanesol is used as a regulator of the PI 3K-Akt signaling pathway, the TRP signaling pathway, the TNF signaling pathway and the p53 signaling pathway, and a suitable regulating concentration is determined, so that it is applied to the field of oral ulcer repair, promotes oral mucosal healing, accelerates the repair speed of oral ulcers, significantly reduces the ulcer area, and achieves effective treatment of oral ulcers. At the same time, this technical solution has no obvious side effects within a certain dosage range, so it has the characteristics of high safety. In addition, the drug prepared based on the appropriate concentration of solanesol can be administered by local application, and the operation is relatively simple. In summary, the technical solution provided by the present invention using a specific concentration of solanesol as an active ingredient of the drug can promote oral ulcer repair, and has the advantages of good efficacy, high safety and convenient application, which improves patient compliance as a whole. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1a , Figure 1b , Figure 1c , Figure 1d , Figure 1e , Figure 1f is a KEGG pathway enrichment analysis diagram in one embodiment, wherein Figure 1a and Figure 1b The results of applying 1μmol / L solanesol are: Figure 1c and Figure 1d The results of applying 5μmol / L solanesol are: Figure 1e and Figure 1f The results of applying 20μmol / L solanesol were: Figure 1a , Figure 1c and Figure 1e For 24h results, Figure 1b , Figure 1d and Figure 1f The results are for 48 hours after application, and the controls are the results without solanesol treatment.

[0016] Figure 2 A flowchart of a treatment plan for oral ulcers in one embodiment;

[0017] Figure 3 The photographs of oral ulcers in mice in one embodiment include an ulcer group and an ulcer+100 μmol / L solanesol group;

[0018] Figure 4 The figure is a hematoxylin-eosin staining image of paraffin sections of oral mucosal tissue of mice in an embodiment, including a normal tissue group, an ulcer group, and an ulcer+100 μmol / L solanesol group;

[0019] Figure 5The figures are photos of oral ulcers in mice in one embodiment, including an ulcer group, an ulcer+100 μmol / L solanesol group, an ulcer+500 μmol / L solanesol group, and an ulcer+1000 μmol / L solanesol group. DETAILED DESCRIPTION

[0020] The technical solution of this patent will be further described in detail below in conjunction with specific implementation methods. It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of this application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by ordinary technicians in the technical field to which this application belongs.

[0021] Example 1

[0022] In this example, GMSM-K cells (a type of oral keratinized epithelial cell) were treated with 1 μmol / L, 5 μmol / L and 20 μmol / L of solanesol, and RNA from the stimulated cells was collected at 24h or 48h for transcriptome sequencing and information analysis. As a control, RNA from cells not treated with solanesol was collected and analyzed using the same operation technique.

[0023] result: Figure 1a to Figure 1f The results of KEGG pathway enrichment analysis are shown in Figure 2. The vertical axis is the name of the KEGG pathway, the horizontal axis of the bar graph is the significance level, and the horizontal axis of the line graph is the number of genes related to the pathway. Figure 1a and Figure 1b The results of applying 1μmol / L solanesol are: Figure 1c and Figure 1d The results of applying 5μmol / L solanesol are: Figure 1e and Figure 1f The results of applying 20μmol / L solanesol were: Figure 1a , Figure 1c and Figure 1e For 24h results, Figure 1b , Figure 1d and Figure 1f The results are for 48 hours of treatment, and the controls are all results without solanesol treatment. It can be found that a series of gene expression changes after solanesol treatment are closely related to biological processes related to cell repair, inflammatory response, cell signal transduction, etc., as follows.

[0024] exist Figures 1a to 1fIn the results, the PI 3K-Akt signaling pathway showed strong enrichment significance, that is, the differential expression of genes in the PI 3K-Ak t signaling pathway between the group treated with solanesol and the group not treated with solanesol was continuously and significantly different, and the genes involved included IL7R, I TGA11, LAMA5, LPAR3, I FNB1, FGF1, NGF, etc.

[0025] This suggests that the PI 3K-Akt signaling pathway may be a direct target of solanesol or is closely related to the mechanism of action of solanesol, that is, solanesol has high sensitivity and specificity for the PI 3K-Akt signaling pathway. In addition, the PI 3K-Akt signaling pathway was significantly enriched in the solanesol group, indicating that solanesol may promote the repair and migration of cells, thereby promoting the repair of oral ulcers.

[0026] exist Figure 1a , Figure 1b and Figure 1f In the experiments, the TRP signaling pathway showed a relatively strong enrichment significance. That is, after applying 1μmol / L solanesol for 24h or 48h, or 20μmol / L solanesol for 48h, compared with the group without solanesol, the genes in the TRP signaling pathway showed significant differential expression, and the genes involved included PRKCQ, I L1 RAP, PI K3R3, etc.

[0027] This indicates that solanesol at 1 μmol / L is sufficient to induce activation of the TRP signaling pathway, and this effect can be sustained over time, that is, solanesol can form a highly specific interaction with the TRP signaling pathway at low doses. In addition, it takes a relatively longer 48 hours to show obvious biological effects after applying 20 μmol / L solanesol, indicating that high concentrations of solanesol require sufficient time to accumulate effects, and this delayed effect may be related to the stronger cell stress response or more complex signaling pathway changes caused by high concentrations. Therefore, on the one hand, solanesol may promote the repair of oral ulcers by affecting the TRP signaling pathway and regulating the inflammatory response. On the other hand, it also shows that solanesol may have a nonlinear dose-response relationship when repairing oral ulcers, that is, low concentrations can stably cause reactions, while medium concentrations may trigger the self-regulatory mechanism of cells, resulting in reduced significance, and high concentrations may exceed the regulatory capacity of cells, resulting in significant effects after a long time.

[0028] exist Figure 1b , Figure 1c , Figure 1d and Figure 1fIn the experiments, the TNF signaling pathway showed a relatively strong enrichment significance. That is, after applying 1μmol / L or 20μmol / L solanesol for 48h, or 5μmol / L solanesol for 24h or 48h, the genes in the TRP signaling pathway showed significant differential expression compared with the group without solanesol administration. The genes involved included CCL2, PIK3R3, IFNB1, etc.

[0029] This suggests that solanesol may act on the TRP signaling pathway through multiple mechanisms: at low concentrations, solanesol may affect the TRP signaling pathway by slowly regulating gene expression or protein activity; at high concentrations, solanesol may act directly through metabolic pathways or cell signal transduction pathways; and at medium concentrations, the oral ulcer repair effect of solanesol may be closest to its targeted mechanism, which can quickly and continuously change the activity of the TRP signaling pathway.

[0030] exist Figure 1d and Figure 1e In the results, the p53 signaling pathway showed a relatively strong enrichment significance, that is, after applying 5μmol / L solanesol for 48h or 20μmol / L solanesol for 24h, the genes in the TRP signaling pathway showed significant differential expression compared with the group without solanesol.

[0031] This suggests that the effect of low-concentration solanesol on the p53 signaling pathway is relatively weak, perhaps because the concentration is not enough to cause changes in key molecules within the pathway, or the effect of solanesol is effectively offset by the cell's regulatory mechanism, so it cannot reach a statistically significant level. At medium concentrations, the effect of solanesol on the p53 signaling pathway is time-dependent, requiring a longer time to accumulate and show a significant effect. At high concentrations, solanesol can quickly activate the p53 signaling pathway, but its effect may be unstable or the cell may regulate through a feedback mechanism over a longer period of time, thereby weakening the effect of the drug.

[0032] When actually developing related drugs and designing dosages using solanesol as the active ingredient, the multiple mechanisms of action of solanesol and the sensitivity of each pathway to drug concentration can be considered to balance efficacy and potential side effects.

[0033] For example, when the PI 3K-Akt signaling pathway is used as the main target to produce therapeutic effects, solanesol can achieve effective treatment at low, medium and high concentrations. In this case, low concentrations are preferred to avoid possible adverse reactions. When the TRP signaling pathway is used as the main target to produce therapeutic effects, solanesol has a sustained effect at low concentrations, but it is relatively difficult to quickly produce therapeutic effects at medium and high concentrations. In this case, low concentrations are preferred. When the TNF signaling pathway or the p53 signaling pathway is used as the main target to produce therapeutic effects, a dynamic dose adjustment strategy can be considered. In the early stage of treatment, medium concentrations (or high concentrations) are preferred to quickly control disease progression, and then adjusted to low concentrations (or medium concentrations) for maintenance treatment to prevent recurrence or long-term side effects. In addition, since the concentration requirements of solanesol are inconsistent when regulating multiple pathways, combination therapy can also be considered, that is, considering the actual situation, multiple drugs are used to target different pathways to optimize the overall therapeutic effect and reduce side effects.

[0034] In summary, by deeply analyzing the effect of solanesol on the transcriptome of GMSM-K cell lines and exploring the response of oral epithelial cells to solanesol, we determined that the appropriate concentration of solanesol can promote the healing of oral mucosa by affecting the gene expression and cell signal transduction of the PI 3K-Akt signaling pathway, TRP signaling pathway, TNF signaling pathway and p53 signaling pathway, thereby promoting ulcer repair. Based on this, an oral ulcer repair regulator and the application of solanesol in the preparation of a regulator that promotes oral ulcer repair were provided.

[0035] Example 2

[0036] like Figure 2 As shown, the present invention uses 40% glacial acetic acid for burning to establish a mouse oral ulcer model, and applies 100-1000 μmol / L of solanesol to the ulcer formation site for treatment, as follows.

[0037] (1) Ten 10-week-old male C57 wild-type mice without specific pathogens were selected and anesthetized by intraperitoneal injection of 0.3% sodium pentobarbital. Then, an oral ulcer model was established in the oral mucosa and tongue tip of the mice using 40% glacial acetic acid by filter paper burning method. After 24 hours, the oral mucosa of the mice was observed to see whether circular sunken lesions were formed to determine whether the ulcer model was successfully established, and the relevant indicators of the ulcer model were recorded, such as apparent indicators such as redness, swelling, pain, erythema halo, and pathological indicators such as epithelial cell nuclear fragmentation and muscle fiber necrosis.

[0038] (2) The mice with successfully established ulcer models were randomly divided into five groups: ulcer group, ulcer + 100μmol l / L solanesol group, ulcer + 500μmol l / L solanesol group, and ulcer + 1000μmol l / L solanesol group. The corresponding substances were applied to the ulcers at regular intervals every day starting from 24 hours after glacial acetic acid burn. Specifically, the ulcer group was used as the control group and the same volume of normal saline was applied. The ulcer + 100μmol l / L solanesol group, ulcer + 500μmol l / L solanesol group, and ulcer + 1000μmol l / L solanesol group were applied with 100μmol l / L solanesol, 500μmol l / L solanesol, and 1000μmol l / L solanesol, respectively.

[0039] (3) The status and ulcer conditions of the mice were recorded and observed daily until the oral ulcers of the mice were completely healed or the mice were killed after 5 days. During this period, the mucosal status, healing degree, healing rate, weight change and histopathological changes of the mice were recorded, and photos of the affected areas and mucosal tissues of the mice were collected, and the mucosal tissues were fixed and sliced.

[0040] result: Figure 3 Comparison photos of the oral mucosa of mice are shown, where Day0 represents the state of the oral mucosa of mice at the beginning of the ulcer model establishment, and Day1 to Day5 represent the state of the 1st to 5th day after treatment with saline or solanesol. It can be seen that obvious ulcer damage can be seen in the oral mucosa of mice in the initial state of both groups, indicating that the mouse ulcer model in both groups was successfully established. On the first day after treatment with saline or solanesol, the ulcer area of ​​mice in the ulcer + 100μmol / L solanesol group began to show signs of healing, while the healing speed of the ulcer group was relatively slow. On the third day, the oral mucosal repair effect of mice in the ulcer + 100μmol / L solanesol group was more obvious, the ulcer area was significantly reduced, the redness and swelling of the mucosa was improved, and white fibrous epithelial hyperplasia was visible, which was significantly better than the ulcer + saline group, indicating that solanesol significantly promoted the repair of oral ulcers in the mouse ulcer model. By the fifth day, the ulcer healing of mice treated with 100μmol / L solanesol was most significant, and the ulcer area was significantly smaller than that of the ulcer group. In summary, it is shown that the use of solanesol can promote the repair of oral ulcers.

[0041] Figure 4 The results of hematoxylin-eosin staining of paraffin sections of mouse oral mucosal tissue are shown. It can be seen that the mucosal tissue of the mouse oral ulcer can be restored to a state close to normal tissue after being treated with solanesol.

[0042] Figure 5The oral mucosal status of mice in the ulcer group, ulcer + 100μmol / L solanesol group, ulcer + 500μmol / L solanesol group, and ulcer + 1000μmol / L solanesol group was compared. It can be seen that compared with the ulcer group, the groups to which solanesol was administered showed accelerated ulcer healing, indicating that solanesol can indeed promote ulcer repair. In addition, solanesol at a concentration of 100μmol / L was the most effective in promoting ulcer healing, indicating that 100μmol / L concentration is the best bioavailability of solanesol in ulcer repair.

[0043] Table 1 Mouse status and oral ulcers

[0044]

[0045] Table 1 summarizes the status of mice in each group and the oral ulcer situation on the 5th day. It can be seen that there were no significant differences in weight changes and histopathological changes among the ulcer group, ulcer + 100μmol l / L solanesol group, ulcer + 500μmol l / L solanesol group, and ulcer + 1000μmol l / L solanesol group, indicating that the administration of an appropriate dose of solanesol to mice with oral ulcers did not induce negative physiological reactions. In addition, compared with the ulcer group, the ulcer + 100μmol l / L solanesol group, the ulcer + 500μmol l / L solanesol group, and the ulcer + 1000μmol l / L solanesol group showed better results in mucosal status, healing degree, and healing ratio, indicating that an appropriate amount of solanesol has a therapeutic effect on oral ulcers. In particular, different concentrations of solanesol showed differences in the degree of healing, among which the mouse group treated with 100 μmol / L solanesol had the best therapeutic effect on the 5th day, indicating that solanesol is most effective in treating oral ulcers at a concentration of around 100 μmol / L.

[0046] According to Example 1, in cell experiments, the effective concentration of solanesol on the PI 3K-Akt signaling pathway, the TRP signaling pathway and the TNF signaling pathway is preferably 1-5 μmol / L. In animal experiments, based on experience and analogy with the application range of other drugs, the preferred concentration range is 100-500 μmol / L. Considering the bioavailability of the drug and its metabolic factors, the actual application concentration can be adjusted between 100-750 μmol / L.

[0047] For cell experiments on the p53 signaling pathway, the preferred concentration of solanesol is 5-20 μmol / L. When used in animal experiments, based on experience and analogy with the application range of other drugs, it is recommended to use 500-2000 μmol / L. After considering the bioavailability and metabolic factors of the drug, the actual application concentration range may be between 750-2000 μmol / L. Combined with the experimental results of Example 2, solanesol has shown good therapeutic effects below 1000 μmol / L, so the preferred concentration used in animal experiments is 750-1000 μmol / L.

[0048] The above are only some embodiments of the present invention. For those skilled in the art, several modifications and improvements can be made without departing from the creative concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. PI 3K-Akt signaling pathway, TRP signaling pathway and TNF signaling pathway oral ulcer repair regulator, characterized in that: The regulator includes solanesol at a concentration of 100-750 μmol / L.

2. A p53 signaling pathway oral ulcer repair regulator, characterized in that: The regulator includes solanesol at a concentration of 750-1000 μmol / L.

3. The use of solanesol in the preparation of oral ulcer repair regulators for PI 3K-Akt signaling pathway, TRP signaling pathway and TNF signaling pathway, characterized in that: The concentration of the solanesol is 100-750 μmol / L.

4. The use of solanesol in the preparation of a p53 signaling pathway oral ulcer repair regulator, characterized in that: The concentration of the solanesol is 750-1000 μmol / L.

Citation Information

Patent Citations

  • Medicine for treating periodontitis

    CN105708794A

  • Application of solanesol in preparation of medicine for preventing, treating or relieving chronic pain

    CN116251080A

  • Application of solanesol in treating anxiety disorder induced by neuroinflammation

    CN116687889A

  • Method for preparing high pure solanesol

    CN1686988A

  • Compositions for preventing and / or treating gingivitis

    US20100129295A1